Sunday, March 15, 2015 12:43:15 PM
As I previously posted, all the options held by insiders are at an exercise price of eight cents or higher. Also any of the four products currently in the pipeline (many more than four with the various orphan indications for MANF) have the potential to be worth many times Amarantus' current market cap.
When thinking of selling a stock which I own at a higher price I ask myself if I didn't own the stock and had just heard about it would I be buying it here. If the answer is yes then I certainly wouldn't sell and in fact would be adding shares as I have been doing.
Amarantus is undervalued and is still unknown to the market at large.
I believe that by the end of the week we'll have a much better idea of Gerald's business plan for 2015.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM